Cargando…
Bisphosphonate-Associated Osteonecrosis of the Jaw: Are We Dealing with a Localized Non-Traditional Calciphylaxis?
The bisphosphonate (BP) family of drugs has been used as a vital component in cancer therapy and many other diseases. One of the main adverse effects related to (BP) is BP-associated osteonecrosis of the jaw (ONJ). Although this condition was first recognized in 2003, the pathophysiologic mechanism...
Autores principales: | Meiller, TF, Almubarak, H, Weikel, DS, Brahim, J, Scheper, MA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263445/ https://www.ncbi.nlm.nih.gov/pubmed/22276079 http://dx.doi.org/10.2174/1874210601206010005 |
Ejemplares similares
-
A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis
por: Scheper, MA, et al.
Publicado: (2010) -
Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression
por: Badros, Ashraf Z., et al.
Publicado: (2021) -
Osteonecrosis of jaw associated with bisphosphonate use
por: Rastogi, Ashu, et al.
Publicado: (2012) -
Bisphosphonate-related osteonecrosis of the jaws (Bronj)
por: Beninati, Francesco, et al.
Publicado: (2013) -
Osteonecrosis of the jaws in patients treated with bisphosphonates
por: Ata-Ali, Fadi, et al.
Publicado: (2012)